Latest stories on SGIOF
Shionogi Wins Japan Approval for JN.1 COVID Booster, Advances Vaccine Platform
TipRanks63 · neutralproduct/pr
Shionogi Wins Pediatric Approval for VTAMA Atopic Dermatitis Cream in Japan
TipRanks63 · neutralproduct/pr
Shionogi Targets Rare Disease Growth With New Pompe Study on S-606001
TipRanks63 · neutralproduct/pr
GSK-owned ViiV wins FDA label expansion for HIV drug Tivicay for newborns
Seeking Alpha67 · bullishproduct/pr
Shionogi & Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Shionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
TipRanks56 · neutralproduct/pr
Shionogi & Co. GAAP EPS of ¥114.78, revenue of ¥163.31B; reaffirms FY 2027 outlook
Seeking Alpha56 · neutralearnings
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Yahoo Top58 · neutralgeneral
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
TipRanks63 · neutralproduct/pr
Shionogi & Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Morningstar63 · neutralproduct/pr